Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02015819 : Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
PhasePhase 1
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Patient has had a prior, histologically-confirmed, diagnosis of a grade III or IV
glioma (including glioblastoma, anaplastic oligodendroglioma, or anaplastic
astrocytoma, gliosarcoma, anaplastic oligodendroglioma, or anaplastic
oligoastrocytoma), or has a prior, histologically-confirmed, diagnosis of a grade II
glioma and now has radiographic findings consistent with a high-grade glioma (grade
III or IV)

- Imaging studies show evidence of recurrent, supratentorial tumor(s). The presence of
infratentorial tumor is allowed as long as the patient also has supratentorial
disease that is amenable to resection or biopsy.

- Patient's high-grade glioma has recurred or progressed after prior treatment with
brain radiation and temozolomide

- Patient has a Karnofsky performance status of >= 70%

- Patient has a life expectancy of >= 3 months

- Female patients of childbearing potential and sexually-active male patients must
agree to use an effective method of contraception while participating in this study;
women of childbearing potential must have a negative pregnancy test =< 2 weeks prior
to registration

- The patient must be in need of a craniotomy for tumor resection or a stereotactic
brain biopsy for the purpose of diagnosis or differentiating between tumor
progression versus treatment-induced effects following radiation therapy +/-
chemotherapy

- Based on the neurosurgeon's judgement, there is no anticipated physical connection
between the post-resection tumor cavity and the cerebral ventricles

- Absolute neutrophil count (ANC) >= 1500 cells/mm^3

- Platelet count >= 100,000 cells/mm^3

- Total bilirubin =< 2.0 mg/dl

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =<
4 times the institutional upper limit of normal

- Serum creatinine =< the institutional upper limit of normal

- There is no limit to the number of prior therapies

- All subjects must have the ability to understand and the willingness to sign a
written informed consent

Exclusion Criteria:

- Patient has anti-human leukocyte antigen (HLA) antibodies specific for HLA antigens
expressed by the NSCs

- Patient has not recovered from any toxicity of prior therapies; an interval of

- At least 6 weeks must have elapsed since taking a nitrosourea-containing
chemotherapy regimen

- At least 4 weeks since completing a non-nitrosourea-containing cytotoxic
chemotherapy regimen (except temozolomide: only an interval of 23 days is
required from the last does administered when patient has been recently treated
with the standard temozolomide regimen of daily for 5 days, repeated every 28
days)

- At least 2 weeks from taking the last dose of targeted agent

- At least 4 weeks from the last dose of bevacizumab

- Patient is unable to undergo a magnetic resonance imaging (MRI)

- Patient is allergic to 5-FC, leucovorin, or 5-FU

- Patient has chronic or active viral infections of the central nervous system (CNS)

- Patient has a coagulopathy or bleeding disorder

- Patient has an uncontrolled illness including ongoing or active infection

- Patient is receiving any other investigational agents, or concurrent biological,
chemotherapy, or radiation therapy

- Patient has had prior therapy with neural stem cells

- Patient is pregnant or breast feeding; pregnant women are excluded from this study;
breastfeeding should be discontinued if the mother is participating in this study

- Patient has another active malignancy

- Non-compliance; a patient has a serious medical or psychiatric illness that could, in
the investigator's opinion, potentially interfere with the safety monitoring
requirements and completion of treatment according to this protocol
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02015819      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740